2020-10-29T11:12:51-05:00 2019-12-31 911194016 CLARK NUBER PS 10900 NE 4TH STREET SUITE 1400 BELLEVUE WA 98004 990 2019-01-01 911893957 THE MAX FOUNDATION MAXF 4257788660 1107 NE 45TH NO 230 SEATTLE WA 98105 PATRICIA M PEARCE CFO & VP, ADMINISTRATION 4257788660 2020-10-22 1 JENNIFER BECKER HARRIS P00183358 4254544919 2020-10-22 65.158.230.194 2020-10-22 13:09:09 PD P DA39A3EE5E6B4B0D3255BFEF95601890AFD80709 2F9BC2A2EFDDEB972A70536C99F264DBD695DA38 2019 2021-01-29 14:40:06Z PATRICIA M PEARCE 1107 NE 45TH NO 230 SEATTLE WA 98105 60039167 0 X WWW.THEMAXFOUNDATION.ORG X 1997 WA AT THE MAX FOUNDATION WE BELIEVE ALL PEOPLE LIVING WITH CANCER DESERVE ACCESS TO THE BEST TREATMENT, CARE, AND SUPPORT. AS SUCH, WE DECREASE PREMATURE MORTALITY OF CANCER BY CHANNELING HUMANITARIAN DONATIONS OF INNOVATIVE ONCOLOGY PRODUCTS TO UNDERSERVED POPULATIONS IN COUNTRIES WHERE THOSE PRODUCTS ARE NOT LOCALLY AVAILABLE. 7 6 23 730 0 0 27791248 57006075 3221057 3013178 4472 -37995 -74110 -63899 30942667 59917359 24004506 45642020 0 0 1822840 2281642 66324 0 478727 2779985 2066078 28673655 49989740 2269012 9927619 9957805 20037868 236108 388552 9721697 19649316 X AT THE MAX FOUNDATION WE BELIEVE ALL PEOPLE LIVING WITH CANCER DESERVE ACCESS TO THE BEST TREATMENT, CARE, AND SUPPORT. WE DECREASE PREMATURE MORTALITY OF CANCER BY CHANNELING HUMANITARIAN DONATIONS OF LIFE-SAVING ONCOLOGY PRODUCTS TO UNDERSERVED POPULATIONS IN COUNTRIES WHERE THOSE PRODUCTS ARE NOT LOCALLY AVAILABLE. 0 0 48302800 45642020 3013178 A KEY FOCUS OF THE ORGANIZATION IS EXPANDING HUMANITARIAN ACCESS TO INNOVATIVE TREATMENTS FOR CANCER IN LOW- AND MIDDLE-INCOME COUNTRIES. THE FOUNDATION AND ITS TAX-EXEMPT SUPPORT ORGANIZATION, MAXAID, RECEIVE DONATIONS OF ONCOLOGY PRODUCTS FROM DRUG MANUFACTURERS AND CHANNEL THEM TO INDIVIDUAL PATIENTS VIA OUR NETWORK HEALTHCARE PROVIDERS AND CANCER TREATMENT CENTERS. THIS ACCESS TO MEDICINES IS ENABLED THROUGH OUR PATIENT-CENTERED TREATMENT ACCESS MODEL KNOWN AS MAX ACCESS SOLUTIONS. OUR PRIMARY CLIENT IS A PATIENT WHO IS TREATED BY ONE OF OUR PARTNER PHYSICIANS, DIAGNOSED WITH A SPECIFIC CANCER, AND PRESCRIBED A MEDICATION FOR WHICH THE ONLY AVAILABLE FORM OF ACCESS IS A HUMANITARIAN CHANNEL THROUGH MAX ACCESS SOLUTIONS. WE USE A SOPHISTICATED WEB-ENGINE PLATFORM DEVELOPED IN-HOUSE TO ALLOW US TO WORK IN REAL TIME WITH HEALTHCARE PROVIDERS AND CREATE INDIVIDUALIZED PROGRAM LIFE CYCLES TO MEET EACH PATIENT'S NEEDS. WE FURTHER ACT AS HEALTHCARE NAVIGATORS FOR THESE PATIENTS, HELPING THEM WALK THROUGH THE ACCESS PROGRAM ENVIRONMENT. IN ORDER TO OPTIMIZE TREATMENT, WITHIN OUR CAPABILITIES WE PROVIDE WRAPAROUND SUPPORT THAT INCLUDES ACCESS TO DIAGNOSTIC TESTING, EMOTIONAL AND LOGISTICAL SUPPORT, INFORMATION RESOURCES AND EDUCATION, AS WELL AS ADVOCATING ON THEIR BEHALF WHEN NEEDED. WE ALSO STRENGTHEN THE COMMUNITIES AROUND PATIENTS BY SUPPORTING PATIENT ORGANIZATIONS AND CREATING AWARENESS INITIATIVES IN LOCAL AND GLOBAL COMMUNITIES. 48302800 1 1 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 1 0 1 1 1 1 0 1 0 0 1 0 1 0 0 0 0 0 0 1 0 1 0 0 0 1 1 1 1 0 0 1 X 16 0 23 1 0 1 IN MY TH AR SF 0 0 0 1 1 0 0 0 0 0 0 X 7 6 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 X X PATRICIA M PEARCE 4257788660 1107 NE 45TH NO 230 SEATTLE WA 98105 PAULA BOULTBEE PRESIDENT 5.00 2.00 X X 0 0 0 PATRICIA GARCIA-GONZALEZ CEO AND SECRETARY OF THE BOARD 50.00 5.00 X X 217705 0 15096 JERRY SCOTT CPA TREASURER 5.00 2.00 X X 0 0 0 TRACEY HIGGINS VICE PRESIDENT 5.00 2.00 X X 0 0 0 CURT MALLOY BOARD MEMBER 5.00 2.00 X 0 0 0 GRANT RUBENSTEIN BOARD MEMBER 5.00 2.00 X 0 0 0 JERALD JERRY RADICH MD BOARD MEMBER 5.00 2.00 X 0 0 0 PATRICIA M PEARCE CHIEF FINANCIAL OFFICER 40.00 2.00 X 174781 0 11119 CRAIG ANDERSON DIRECTOR OF IT 40.00 0.00 X 114431 0 12381 MICHAEL WRIGGLESWORTH SR. DIRECTOR OF PROGRAMS STRATEGY 40.00 0.00 X 112670 0 0 NEIL PARRY SENIOR SUPPLY CHAIN MANAGER 40.00 0.00 X 105067 0 9829 724654 0 48425 5 0 1 0 TANNERGAP INC 1808 ASSOCIATES LANE STE A CHARLOTTE NC 28217 SUPPLY CHAIN MANAGEMENT 459768 1 141873 56864202 55737893 57006075 PATIENT CARE 624100 2785875 2785875 MEDICAL TEST KITS 624100 227303 227303 3013178 15 15 10 10 300 38310 -38010 -38010 -38010 1020 141873 83498 -82478 -82478 REIMBURSEMENTS 900099 18569 18569 18569 59917359 3013178 0 -101894 10000 10000 45632020 45632020 418701 185880 191356 41465 59423 59423 1548378 755748 491351 301279 113352 54766 35126 23460 141788 62293 51634 27861 18092 18092 80886 80886 149891 83821 44369 21701 90590 45622 35697 9271 49896 18457 25151 6288 170855 105448 52201 13206 259789 211566 32720 15503 5462 624 4314 524 51868 25895 16471 9502 17433 3673 13760 COUNTRY REPRESENTATIVES 560033 560033 DISTRIBUTION & SHIPPING 487531 487531 123752 115085 8667 49989740 48302800 1208213 478727 1738682 756835 63673 60155 242770 50000 622 505852 6286524 16760380 19839 58020 466187 150337 80920 315850 1524775 1530776 9957805 20037868 228930 269769 7178 118783 236108 388552 X 2763214 2393700 6958483 17255616 9721697 19649316 9957805 20037868 9927619 0 X X 0 1 X 1 0 X 2765925 13925957 18308593 27791248 57006075 119797798 2765925 13925957 18308593 27791248 57006075 119797798 103025521 16772277 4605 5680 5434 4483 25 20227 1120 4968 3693 1022 18869 29672 119847697 13386488 0.13990 0.17270 X THE MAX FOUNDATION QUALIFIES AS A PUBLICLY SUPPORTED CHARITY UNDER THE FACTS AND CIRCUMSTANCES EXCEPTION PROVIDED TO IRC SECTION 509(A)(1) CHARITIES UNDER TREAS. REG. SEC. 1.170A-9(E)(3). THE FOUNDATION DOES NOT RECEIVE AT LEAST ONE THIRD OF ITS SUPPORT FROM THE PUBLIC. IT DOES HOWEVER MEET THE TESTS REQUIRED UNDER THE FACTS AND CIRCUMSTANCE TEST: I. THE FOUNDATION NORMALLY MEETS THE PUBLIC SUPPORT TEST AS PROVIDED IN THE REGULATIONS. THE AGGREGATE PUBLIC SUPPORT PERCENTAGE FOR THE YEARS ENDED DECEMBER 31, 2017, 2016, 2015, 2014, AND 2013 IS 27.73%, 41.45%, 30.50%, 37.79%, AND 40.92%, RESPECTIVELY. II. THE FOUNDATION CARRIES ON A BONA FIDE CONTINUOUS PUBLIC SOLICITATIONS PROGRAM. ITS FUNDRAISING EFFORTS INCLUDE ANNUAL MAILINGS TO SOLICIT FUNDS, PUBLISHING OF AN ANNUAL REPORT TO EDUCATE ITS DONOR BASE AND FURTHER SOLICIT DONATIONS, AND OTHER FUNDRAISING ACTIVITES. IN 2019 THE FOUNDATION HELD ITS SECOND FUNDRAISING GALA, RAISING NEARLY $143,000. THIS MARKED A SUBSTANCIAL INCREASE FOR OUR 2017 FIRST GALA WHICH RAISED OVER $98,000. IN 2017 AND 2018 WE ALSO HAD INTERNATIONAL FUNDRAISING EVENTS CALLED MAX GLOBAL EXPERIENCE WHICH RAISED OVER $109,000 AND OVER $80,000, RESPECTIVELY, FROM THE GENERAL PUBLIC. SINCE 2017 FIVE MULTINATIONAL PHARMACEUTICAL COMPANIES JOINED THE FOUNDATION IN WHAT WE CALL A HUMANITARIAN PARTNERSHIP FOR ACCESS TO CANCER TREATMENT (PACT). THROUGH THESE HUMANITARIAN COLLABORATIONS, EACH COMPANY HAS COMMITTED TO DONATE PRESCRIBED MEDICATIONS FOR A DIFFERENT NUMBER OF PATIENTS WITHIN THEIR CAPABILITIES, AND ALL HAVE COMMITTED THEIR SUPPORT FOR AS LONG AS EACH PATIENT NEEDS IT. III. DURING THE YEARS ENDED DECEMBER 31, THE FOUNDATION HAD THE FOLLOWING SUPPORTERS, RESPECTIVELY: 2015:INDIVIDUALS - 307 CORPORATIONS - 8 FOUNDATIONS - 1TOTAL - 3162016:INDIVIDUALS - 371 CORPORATIONS - 24 FOUNDATIONS - 2TOTAL - 3972017:INDIVIDUALS - 676 CORPORATIONS - 35 FOUNDATIONS - 2TOTAL - 7132018:INDIVIDUALS - 377 CORPORATIONS - 42 FOUNDATIONS - 2TOTAL - 4212019:INDIVIDUALS - 289CORPORATIONS - 43FOUNDATIONS - 1TOTAL - 333 IV. THE PUBLIC NATURE OF THE FOUNDATION'S GOVERNING BOARD THE FOUNDATION HAS A BOARD OF DIRECTORS THAT INCLUDES PROFESSIONALS, COMMUNITY LEADERS, AND OTHER PERSONS WITH EXPERTISE IN DIFFERENT DISCIPLINES. IN ADDITION, THE FOUNDATION HAS A MEDICAL ADVISORY BOARD AND A STRATEGIC INNOVATION ADVISORY BOARD. OUR MEDICAL ADVISORY BOARD INCLUDES SPECIALISTS WHO ARE KEY OPINION LEADERS IN THE FIELD OF ONCOLOGY AND HEMATOLOGY. BASED ALL AROUND THE WORLD THESE EXPERT PHYSICIANS ARE FORMATIVE IN LEADING RESEARCH AND MANAGING PATIENT CARE AT THEIR CENTERS OF EXCELLENCE. OUR STRATEGIC INNOVATION ADVISORY BOARD HAIL FROM BOTH THE PUBLIC AND PRIVATE SECTORS AND INCLUDE GLOBAL LEADERS FROM THE FIELD OF GLOBAL HEALTH, FUNDRAISING, BUSINESS, AND COMMUNICATIONS. V. THE FOUNDATION SUPPORTS GLOBAL HEALTH EFFORTS BY MAKING TREATMENT, CARE, AND SUPPORT AVAILABLE IN LOWER INCOME COUNTRIES AND THEREBY PREVENTING AVOIDABLE CANCER DEATHS AROUND THE WORLD HELPING TO CLOSE THE CANCER DIVIDE BETWEEN HIGH INCOME AND LOWER INCOME COUNTRIES THROUGH HUMANITARIAN ACCESS TO TREATMENT, CARE AND SUPPORT. CREATING A MODEL THAT ENABLES THE PRIVATE SECTOR TO HELP CANCER PATIENTS IN NEED. STRENGTHENING HEALTH SYSTEMS AND LOCAL SUPPORTS THROUGH WRAPAROUND SERVICES FOR PATIENTS AND THEIR COMMUNITIES.VI. MAX ACCESS SOLUTIONS IS THE FOUNDATION'S OPERATIONAL PROGRAM THROUGH WHICH HUMANITARIAN DONATIONS OF APPROVED ONCOLOGY PRODUCTS ARE CHANNELED TO PATIENTS IN NEED. MAX ACCESS SOLUTIONS IS MEANT TO BE A BRIDGE FOR ACCESS TO TREATMENT SPECIFICALLY WITHIN LOW- AND MIDDLE-INCOME COUNTRIES WHERE THE BURDEN OF DISEASE IS HIGH AND LOCAL GOVERNMENT ACCESS PROGRAMS MAY NOT BE CURRENTLY FEASIBLE. WITHIN MAX ACCESS SOLUTIONS, COMPANIES DONATE PRODUCT TO THE FOUNDATION AND THE ORGANIZATION CHANNELS PRODUCT AT ITS DISCRETION TO PATIENTS IN NEED THROUGH THEIR TREATING PHYSICIAN AND WITHIN THE SCOPE OF ITS COLLABORATION AGREEMENTS. VETTED HEALTH CARE PROVIDERS IN LOW- AND MIDDLE-INCOME COUNTRIES INITIATE THE PRODUCT REQUEST AND MANAGE TREATMENT OF PATIENTS RECEIVING PRODUCT FROM THE FOUNDATION. THE FOUNDATION WORKS THROUGH A THIRD-PARTY LOGISTICS PROVIDER WHO, AS ITS AGENT, RECEIVES PRODUCT FROM MANUFACTURERS AND SHIPS IT TO END USERS ON THE ORGANIZATION'S BEHALF.AT THE CENTER OF OUR MODEL IS A PATIENT WHO HAS BEEN DIAGNOSED WITH CANCER BY ONE OF OUR PARTNER PHYSICIANS AND PRESCRIBED A TREATMENT IN OUR PORTFOLIO FOR WHICH NO LOCAL ACCESS EXISTS. WORKING IN COLLABORATION WITH A ROBUST NETWORK OF LEADING CANCER TREATING INSTITUTIONS AND PHYSICIANS, DRUG MANUFACTURERS, AN INTERNATIONAL DISTRIBUTOR, AND LOCAL PATIENT SUPPORT ORGANIZATIONS, WE PROVIDE HUMANITARIAN ACCESS TO THE TREATMENT WITH THE AIM THAT EACH REQUIRED DAILY DOSE REACHES THE INTENDED PATIENT AT THE RIGHT TIME, WHILE STRENGTHENING THE LOCAL HEALTHCARE SYSTEM.IN 2019, THE FOUNDATION AND ITS TAX-EXEMPT SUPPORT ORGANIZATION, MAXAID, DELIVERED 257,670 AND 4,383,749 DAILY DOSES, RESPECTIVELY, INTO THE HANDS OF PATIENTS. WE WORKED WITH A GLOBAL NETWORK OF 277 DOCTORS WHO REFERRED CANCER PATIENTS TO US FROM AROUND THE WORLD. WE OVERSAW DRUG SHIPMENTS TO 74 COUNTRIES. THE FOUNDATION AND MAXAID TRACKED OVER 1,231 AND 15,963 INDIVIDUAL PATIENTS, RESPECTIVELY, IN OUR REAL-TIME TRACKING SYSTEM SPECIFICALLY DEVELOPED TO MONITOR EACH PATIENT'S TREATMENT LIFECYCLE. SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: MISCELLANEOUS INCOME - 2015 AMOUNT: $ 1,120. 2016 AMOUNT: $ 4,968. 2017 AMOUNT: $ 3,693. 2018 AMOUNT: $ 1,022. 2019 AMOUNT: $ 18,869. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 243580 18736 224844 222607 131601 91006 315850 LEASE DEPOSIT 15048 DUE FROM MAXAID 1515728 1530776 1 CENTRAL AMERICA AND THE CARIBBEAN 0 0 GRANTS TO RECIPIENTS IN REGION 538000 EAST ASIA AND THE PACIFIC 0 0 GRANTS TO RECIPIENTS IN REGION 16126000 EUROPE (INCLUDING ICELAND AND GREENLAND) 0 0 GRANTS TO RECIPIENTS IN REGION 192000 RUSSIA AND NEIGHBORING STATES 0 0 GRANTS TO RECIPIENTS IN REGION 2895000 SOUTH AMERICA 0 0 GRANTS TO RECIPIENTS IN REGION 801000 SOUTH ASIA 0 0 GRANTS TO RECIPIENTS IN REGION 8802000 SUB-SAHARAN AFRICA 0 0 GRANTS TO RECIPIENTS IN REGION 15698000 MIDDLE EAST AND NORTH AFRICA 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 208000 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 FUNDRAISING CENTRAL AMERICA AND THE CARIBBEAN 0 3 PROGRAM SERVICES EDUCATIONAL WORKSHOPS, PATIENT COUNSELING 160000 EAST ASIA AND THE PACIFIC 2 10 PROGRAM SERVICES EDUCATIONAL WORKSHOPS, PATIENT COUNSELING 42000 RUSSIA AND NEIGHBORING STATES 0 2 PROGRAM SERVICES EDUCATIONAL WORKSHOPS, PATIENT COUNSELING 66000 SOUTH AMERICA 1 6 PROGRAM SERVICES EDUCATIONAL WORKSHOPS, PATIENT COUNSELING 15000 SOUTH ASIA 1 21 PROGRAM SERVICES EDUCATIONAL WORKSHOPS, PATIENT COUNSELING 44000 SUB-SAHARAN AFRICA 1 7 PROGRAM SERVICES EDUCATIONAL WORKSHOPS, PATIENT COUNSELING 43000 0 0 5 49 5 49 45260000 370000 45630000 CENTRAL AMERICA AND THE CARIBBEAN DIAGNOSTIC TESTING 20680 DIAGNOSTIC EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT CENTRAL AMERICA AND THE CARIBBEAN DIAGNOSTIC TESTING 15750 DIAGNOSTIC EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT EAST ASIA AND THE PACIFIC DIAGNOSTIC TESTING 10750 DIAGNOSTICS EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT RUSSIA AND NEIGHBORING STATES DIAGNOSTIC TESTING 6775 DIAGNOSTICS EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT SOUTH AMERICA DIAGNOSTIC TESTING 9970 DIAGNOSTICS EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT CENTRAL AMERICA AND THE CARIBBEAN DIAGNOSTIC TESTING 28770 DIAGNOSTICS EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT RUSSIA AND NEIGHBORING STATES DIAGNOSTIC TESTING 20700 DIAGNOSTICS EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT RUSSIA AND NEIGHBORING STATES DIAGNOSTIC TESTING 19500 DIAGNOSTICS EQUIPMENT NON-PROFIT PREFERENTIAL PRICING AGREEMENT 8 0 DRUG CENTRAL AMERICA AND THE CARIBBEAN 41 537691 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG EAST ASIA AND THE PACIFIC 346 16125874 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG EUROPE (INCLUDING ICELAND AND GREENLAND) 4 191891 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG MIDDLE EAST AND NORTH AFRICA 14 207648 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG RUSSIA AND NEIGHBORING STATES 90 2894623 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG SOUTH AMERICA 29 800517 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG SOUTH ASIA 186 8802373 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG SUB-SAHARAN AFRICA 521 15697885 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE 1 1 0 0 0 0 PART I, LINE 2: ALL GRANTS TO FOREIGN ENTITIES OR INDIVIDUALS ARE MADE SUBJECT TO A WRITTEN AGREEMENT OR AWARD LETTER THAT CLEARLY DEFINES DELIVERABLES. THE MAX FOUNDATION MAINTAINS A PROGRAM DATABASE IN ORDER TO TRACK DOCUMENTATION OF GRANT REQUESTS, QUALIFIED GRANTEES, AND FULFILMENT OF GRANT REQUESTS. PROGRAM STAFF MEMBERS MONITOR THE EXECUTION OF GRANT DELIVERABLES TO ENSURE THAT THE TERMS OF THE AGREEMENT ARE FULFILLED ON A TIMELY BASIS. PART I, LINE 3: THE EXPENDITURES REPORTED ON SCHEDULE F, PART I, LINE 3 ARE ON THE ACCRUAL BASIS OF ACCOUNTING. PART III ACCOUNTING METHOD: PART IV, LINE 1: FORM 926 IS NOT REQUIRED TO BE FILED BECAUSE THE TRANSFER TO A FOREIGN CORPORATION DOES NOT MEET THE REPORTING REQUIREMENTS IN IRC SEC. 6038(A)(1)(A). GALA 142893 141873 1020 9885 30611 4000 39002 142893 141873 1020 9885 30611 4000 39002 83498 -82478 1 FRED HUTCHINSON CANCER RESEARCH CENTER 1100 FAIRVIEW AVE N - PO BOX 19024 SEATTLE WA 98109 237156071 501(C)(3) 10000 SUPPORT FOR "SPOT ON" DIAGNOSTIC TESTING 1 PART I, LINE 2: ALL GRANTS TO US ENTITIES ARE MADE SUBJECT TO AN AWARD LETTER THAT CLEARLY DEFINES THE GRANTS SCOPE. PROGRAM TEAM MEMBERS MONITOR THE EXECUTION OF GRANT DELIVERABLES TO ENSURE THAT THE TERMS OF THE AGREEMENT ARE FULFILLED ON A TIMELY BASIS. X X X 0 0 0 0 0 0 0 0 0 PATRICIA GARCIA-GONZALEZ CEO AND SECRETARY OF THE BOARD 207705 0 10000 0 0 0 0 0 15096 0 232801 0 0 0 PATRICIA M PEARCE CHIEF FINANCIAL OFFICER 174781 0 0 0 0 0 0 0 11119 0 185900 0 0 0 INES GARCIA-GONZALEZ SEE PART V 59423 SEE PART V 0 SCH L, PART IV, BUSINESS TRANSACTIONS INVOLVING INTERESTED PERSONS: (A) NAME OF PERSON: INES GARCIA GONZALEZ(B) RELATIONSHIP BETWEEN INTERESTED PERSON AND ORGANIZATION: FAMILY MEMBER OF PATRICIA GARCIA-GONZALEZ, CEO.(D) DESCRIPTION OF TRANSACTION: CONTRACTOR X 733450 55737893 COMM VOL AVG WHOLESALE 0 0 1 0 PART I, COLUMN (B): THE NUMBER IN COLUMN B REPRESENTS THE NUMBER OF TABS CONTRIBUTED. FORM 990, PART I, LINE 6, VOLUNTEERS: THERE ARE SIX VOLUNTEER BOARD MEMBERS. PARTNER HEALTHCARE PROVIDERS VOLUNTEER THEIR TIME TO FULFILL ALL OBLIGATIONS RELATED TO PRESCRIBING, APPLYING FOR TREATMENT ACCESS REQUESTS ON BEHALF OF INDIVIDUAL PATIENTS, SUPPORT LOGISTICS AND OBTAINING IMPORT PERMITS FROM LOCAL HEALTHCARE AUTHORITIES, OVERSEE USE AND DISPENSATION OF DONATED PRODUCTS AND OTHER ACTIVITIES RELATED TO THEIR OBLIGATIONS WITHIN THE MAX ACCESS SOLUTIONS. IN 2019, THERE WERE 300 HEALTHCARE PROVIDERS IN OUR NETWORK. FORM 990, PART VI, SECTION B, LINE 11B THE TAX RETURN IS PREPARED BY AN OUTSIDE ACCOUNTANT. AFTER PREPARATION, THE FINANCE COMMITTEE PERFORMS A REVIEW OF THE RETURN. THE RETURN IS THEN FILED WITH THE IRS. A COPY IS PROVIDED TO THE BOARD OF DIRECTORS PRIOR TO FILING WITH THE INTERNAL REVENUE SERVICE. FORM 990, PART VI, SECTION B, LINE 12C THE BOARD HAS ADOPTED A CONFLICT OF INTEREST POLICY AND THE POLICY IS REVIEWED ON AN ANNUAL BASIS. EACH YEAR, BOARD MEMBERS AND OFFICERS MUST REVIEW THE POLICY AND DETERMINE IF ANY CONFLICT OF INTERESTS EXIST. ANNUALLY, THE DISCLOSURES WERE REVIEWED BY THE EXECUTIVE ASSISTANT. SHOULD A CONFLICT ARISE, IT WOULD BE REVIEWED BY THE CFO, CEO AND BOARD TREASURER. NO BOARD MEMBER OR OFFICER MAY VOTE ON ANY MATTER UNDER CONSIDERATION IN WHICH SUCH PERSON HAS A CONFLICT OF INTEREST. FURTHER, ANY PERSON WITH A MATERIAL CONFLICT OF INTEREST IN ANY DECISION SHOULD BE ABSENT FROM THE ROOM DURING THE BOARD'S REVIEW, INCLUDING ITS VOTE, ON THE DECISION IN QUESTION. FORM 990, PART VI, SECTION B, LINE 15 THE CEO HAS A CONTRACT WITH THE BOARD, UPDATED AND APPROVED ON DECEMBER 19, 2019. IN THIS CONTRACT, A BASE SALARY AND A YEARLY PERCENTAGE INCREASE HAS BEEN ESTABLISHED, AS WELL AS A YEARLY BONUS. AN HR CONSULTANT, COMPENSATION ANALYSIS AND A WRITTEN PERFORMANCE EVALUATION ALL WENT INTO THE RENEWAL OF THE CEO CONTRACT DURING 2019. THE CFO WAS OFFICIALLY HIRED AS AN EMPLOYEE IN JULY 2018. BOTH THE CEO AND THE BOARD REVIEWED AND DETERMINED COMPENSATION. FORM 990, PART VI, SECTION C, LINE 19 THE GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE PROVIDED UPON REQUEST. FORM 990, PART XII, LINE 2B AND PART IV LINE 12A ACTIVITY REPORTED ON THIS FORM 990 AND ITS AUDITED FINANCIAL STATEMENTS INCLUDES ALL ACTIVITY FOR ENTITIES REPORTED ON SCHEDULE R, PART IV AS WELL AS ALL BRANCH OFFICES AND LOCATIONS INCLUDING INDIA, THAILAND AND SOUTH AFRICA. MAXSTATION MALAYSIA SDN BHD UNIT 1302 LOBBY 1 BLOCK A DAMAN SELANGOR MY 320492996 PATIENT ORIENTED PROGRAMS MY 108488 28130 THE MAX FOUNDATION MAXAID 1107 NE 45TH NO 230 SEATTLE WA 98105 352577906 SUPPORT MAX FOUNDATION WA 501(C)(3) LINE 12A, I THE MAX FOUNDATION 1 THE MAX FOUNDATION SOUTH AFRICA TRUST 10 COSMOSPLACE DOORNPOORT PRETORIA SF 0186 TO SUPPORT MAX FOUNDATION SF MAX FOUNDATION T -28570 1085 1.00000 1 0 1 0 0 0 0 0 0 0 0 0 1 0 1 1 0 1 0 0 MAXAID L 2630250 BOOK